Golden ticket? Regeneron, Sanofi buy priority review voucher for alirocumab

Regeneron Pharmaceuticals and Sanofi paid $67.5m to buy BioMarin Pharmaceutical's rare pediatric disease priority review voucher, which could help their cholesterol-reducing therapy alirocumab win US FDA approval before Amgen's competing biologic evolocumab.

Regeneron and Sanofi reported early on 30 July that their proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor met the primary efficacy endpoints in nine different Phase III ODYSSEY clinical trials, clearing the way for a biologic license application (BLA) submission to the FDA by the end of the year